白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2013年
7期
406-409
,共4页
任思楣%陆红%闫颖%王海飞%谢波
任思楣%陸紅%閆穎%王海飛%謝波
임사미%륙홍%염영%왕해비%사파
间充质干细胞%白血病,髓样,急性%白细胞介素17%Th17细胞
間充質榦細胞%白血病,髓樣,急性%白細胞介素17%Th17細胞
간충질간세포%백혈병,수양,급성%백세포개소17%Th17세포
Mesenchymal stem cells%Leukemia,myeloid,acute%Interleukin-17%Th17 cells
目的 探讨人骨髓来源的间充质干细胞(BMSC)在体外对外周血Th17细胞及IL-17的调节作用.方法 用淋巴细胞分离液以密度梯度离心法分离3例急性髓系白血病(AML)、3例急性淋巴细胞白血病(ALL)、1名健康人BMSC及健康人外周血单个核细胞(PBMC)并传代培养;酶联免疫吸附法(ELISA)检测培养上清中的IL-17;流式细胞术检测共培养的健康人外周血中Th17细胞所占百分比.结果 AML患者BMSC与健康人PBMC共培养后,上清中IL-17表达水平为(292.32±37.25) pg/ml,与健康人BMSC与PBMC共培养上清中的IL-17水平[(169.64±17.47)pg/ml]相比,差异有统计学意义(P< 0.01);ALL患者的BMSC与PBMC共培养后,上清中的IL-17表达水平为(159.89±23.71)pg/ml,与健康人BMSC与PBMC共培养上清的差异无统计学意义(P>0.05).健康人、ALL和AML患者BMSC与健康人PBMC共培养体系中Th17细胞的百分比分别为(10.13±2.19)%、(13.77±4.04)%、(21.53±5.05)%,AML患者与健康人间差异有统计学意义(P<0.01),ALL患者与健康人间差异无统计学意义(P>0.05).结论 AML患者BMSC促进外周血CD4+T细胞分化产生Th17细胞,AML患者BMSC可能在免疫抑制调节中发挥作用.
目的 探討人骨髓來源的間充質榦細胞(BMSC)在體外對外週血Th17細胞及IL-17的調節作用.方法 用淋巴細胞分離液以密度梯度離心法分離3例急性髓繫白血病(AML)、3例急性淋巴細胞白血病(ALL)、1名健康人BMSC及健康人外週血單箇覈細胞(PBMC)併傳代培養;酶聯免疫吸附法(ELISA)檢測培養上清中的IL-17;流式細胞術檢測共培養的健康人外週血中Th17細胞所佔百分比.結果 AML患者BMSC與健康人PBMC共培養後,上清中IL-17錶達水平為(292.32±37.25) pg/ml,與健康人BMSC與PBMC共培養上清中的IL-17水平[(169.64±17.47)pg/ml]相比,差異有統計學意義(P< 0.01);ALL患者的BMSC與PBMC共培養後,上清中的IL-17錶達水平為(159.89±23.71)pg/ml,與健康人BMSC與PBMC共培養上清的差異無統計學意義(P>0.05).健康人、ALL和AML患者BMSC與健康人PBMC共培養體繫中Th17細胞的百分比分彆為(10.13±2.19)%、(13.77±4.04)%、(21.53±5.05)%,AML患者與健康人間差異有統計學意義(P<0.01),ALL患者與健康人間差異無統計學意義(P>0.05).結論 AML患者BMSC促進外週血CD4+T細胞分化產生Th17細胞,AML患者BMSC可能在免疫抑製調節中髮揮作用.
목적 탐토인골수래원적간충질간세포(BMSC)재체외대외주혈Th17세포급IL-17적조절작용.방법 용림파세포분리액이밀도제도리심법분리3례급성수계백혈병(AML)、3례급성림파세포백혈병(ALL)、1명건강인BMSC급건강인외주혈단개핵세포(PBMC)병전대배양;매련면역흡부법(ELISA)검측배양상청중적IL-17;류식세포술검측공배양적건강인외주혈중Th17세포소점백분비.결과 AML환자BMSC여건강인PBMC공배양후,상청중IL-17표체수평위(292.32±37.25) pg/ml,여건강인BMSC여PBMC공배양상청중적IL-17수평[(169.64±17.47)pg/ml]상비,차이유통계학의의(P< 0.01);ALL환자적BMSC여PBMC공배양후,상청중적IL-17표체수평위(159.89±23.71)pg/ml,여건강인BMSC여PBMC공배양상청적차이무통계학의의(P>0.05).건강인、ALL화AML환자BMSC여건강인PBMC공배양체계중Th17세포적백분비분별위(10.13±2.19)%、(13.77±4.04)%、(21.53±5.05)%,AML환자여건강인간차이유통계학의의(P<0.01),ALL환자여건강인간차이무통계학의의(P>0.05).결론 AML환자BMSC촉진외주혈CD4+T세포분화산생Th17세포,AML환자BMSC가능재면역억제조절중발휘작용.
Objective To investigate the in vitro effects of human bone marrow derived mesenchymal stem cells (hBMSC) on Th17 cells of the human peripheral blood.Methods The density gradient centrifugation combined with lymphocyte separation medium was used to isolate hBMSC,which were then cultured.Cytokine IL-17 in the peripheral blood from a healthy person was measured by enzyme-linked immunosorbent assay (ELISA).Proportion of Th17 cells was evaluated by flow cytometry.Results The expression level of IL-17 in spent culture supernatant of the healthy person PBMC and AML hBMSC was (292.32±37.25) pg/ml,and was significantly higher than that of the healthy person PBMC and healthy hBMSC [(169.64±17.47) pg/ml,P < 0.01].There was no significant difference between the expression level of IL-17 in spent culture supernatant of the healthy person PBMC and ALL hBMSC [(159.89±23.71) pg/ml] and the level of the healthy person PBMC and hBMSC.The percentages of Th17 cells of co-culture systems from hBMSC,ALL-hBMSC,and AML-hBMSC and PBMC were (10.13±2.19) %,(13.77±4.04) % and (21.53±5.05) %,respectively,with the result between AML patients and healthy people being statistically different (P < 0.01).ALL patients and healthy people showed no difference (P > 0.05).Conclusion AML-hBMSC promotes the CD~ T cells to generate Th17 cells,which suggests that the MSC from AML marrow may play a role in the regulation of immune suppression.